ACADStockAcadia Pharmaceuticals Inc
Verdicts genuinely change. Free email alert the moment ACAD's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Acadia Pharmaceuticals Inc (ACAD) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 456 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for ACAD — this runs off the critical path so the page paints first. It will appear here on its own.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $18M | 0.0% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $1M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 45.50 | NEUTRAL |
| Stochastic %K (14) | 83.97 | SELL |
| CCI (20) | 146.04 | SELL |
| Williams %R (14) | -16.03 | SELL |
| MACD (12,26,9) | 0.39 | BUY |
| ROC (10) | 7.69 | BUY |
| Momentum (10) | 1.47 | BUY |
| EMA (10) | 20.23 | BUY |
| SMA (10) | 20.20 | BUY |
| EMA (20) | 20.56 | BUY |
| SMA (20) | 19.85 | BUY |
| EMA (30) | 21.27 | SELL |
| SMA (30) | 20.63 | SELL |
| EMA (50) | 22.45 | SELL |
| SMA (50) | 23.74 | SELL |
| EMA (100) | 23.56 | SELL |
| SMA (100) | 24.72 | SELL |
| EMA (200) | 23.77 | SELL |
| SMA (200) | 23.68 | SELL |
About Acadia Pharmaceuticals Inc
Healthcare · Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-10-14
Stop 18.49 Now 20.59 Target 19.63
🟡 BULLISH LEAN
The main driver: outperforming the market by 5.7%, RSI in healthy zone, Wall Street broadly bullish. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert ACAD [level]` to catch the entry, or `!plan ACAD` to size small.
Scores: 3 bullish / 2 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 64 |
| ⏰ 4H | BULLISH | 40 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
CLUSTER SELL 0 buys · 5 sells
Recent: Schneyer Mark C. sold 77120 sh @ $29.00 (2026-08-06); Schneyer Mark C. sold 67828 sh @ $29.34 (2026-08-06); Schneyer Mark C. sold 67828 sh @ $29.00 (2026-08-05)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-27 · Asset managers net 923449 (+22072)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.